We've been cooking up something exciting with comedian, actor, author—and now celebrity chef—Kenan Thompson! He's working with us on a new campaign to spread the word about GERD, treating persistent heartburn, and how people can talk to their doctors about exploring treatment options. Learn more about our work with Kenan and his experience living with Non-Erosive GERD: https://bit.ly/3Y5hTRJ
Phathom Pharmaceuticals
Biotechnology Research
Florham Park, New Jersey 28,060 followers
Going beyond to advance treatments for patients with acid-related disorders
About us
Phathom Pharmaceuticals (Nasdaq: PHAT) is a biopharmaceutical company committed to transforming the treatment landscape for people suffering from gastrointestinal (GI) diseases related to acid. We are a team of highly driven pharmaceutical professionals who are passionate about our mission to address unmet needs for patients and improve their quality of life. By ensuring all voices are heard, holding ourselves accountable to be equitable and just, and authentically supporting the people and communities impacted by our work, we strive to create a sense of inclusion and belonging. We are looking for self-motivated, creative problem solvers who are excited by the idea of working in a fast-paced start-up environment and contributing to our growth.
- Website
-
http://phathompharma.com
External link for Phathom Pharmaceuticals
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Florham Park, New Jersey
- Type
- Public Company
- Founded
- 2018
- Specialties
- Biotechnology, Pharmaceuticals, R&D, Commercialization, Gastrointestinal , GI, Innovation, and Drug development
Locations
-
Primary
100 Campus Drive
Suite 102
Florham Park, New Jersey 07932, US
-
2150 E Lake Cook Rd
Suite 800
Buffalo Grove, Illinois 60089, US
-
70 Willow Rd
Suite 200
Menlo Park, California 94025, US
Employees at Phathom Pharmaceuticals
Updates
-
Join us on Thursday, May 1 at 8:00 AM ET for a live conference call with Phathom management to discuss our first quarter 2025 financial results and provide business updates. Read more: https://bit.ly/3GnJdVr
-
This #AdministrativeProfessionalsDay, we’re celebrating the incredible administrative professionals who help keep Phathom running seamlessly. Your dedication, attention to detail, and hard work do not go unnoticed. We’re truly grateful for everything you do to support our teams every day!
-
-
We’re hopping into the weekend with warm wishes to all who celebrate #Easter! In observance of the holiday, Phathom offices are closed today for Good Friday. Wishing everyone a joyful and restful weekend. #HappyEaster
-
-
We’re excited to welcome Ted Schroeder to Phathom’s Board of Directors. Ted brings more than three decades of biopharma leadership, with a proven track record of developing and commercializing innovative treatments, scaling high-growth organizations, and delivering long-term value for patients and shareholders. Learn more: https://bit.ly/42yHtjy
-
We are excited to be back at #PriMedSouthwest this year! Stop by booth 318 from April 10-12 in Houston, TX, to connect with our Medical Science Liaisons (MSLs) and learn about the latest research from Phathom in the field of gastrointestinal (GI) disorders. See you in the Lone Star State! Pri-Med
-
-
Join members of the #Phathom management team for a fireside chat at the 24th Annual Needham & Company Virtual Healthcare Conference on Tuesday, April 8, 2025, at 10:15 a.m. ET. Learn more: https://bit.ly/4ia0gYw
-
This morning, we announced that Steven Basta has been appointed as our next President and Chief Executive Officer, effective today. Steve will lead Phathom at an important stage in the Company’s commercial growth journey. He is an accomplished biopharmaceutical leader with a strong track record of developing and commercializing novel treatments and building growth-oriented organizations. Steve succeeds Terrie Curran – we thank Terrie for her leadership and role in advancing Phathom from clinical stage to a commercial company. Learn more: https://bit.ly/4i6MFBe
-
-
As #WomensHistoryMonth2025 comes to a close, we honor the trailblazing women who have paved the way for progress, and those who continue to break barriers every day. We are especially grateful for the incredible women of our #PhathomPhamily who lead with excellence, inspire future generations, and drive meaningful change. Their impact extends far beyond this month, and we remain committed to fostering empowerment and opportunity for all. Let’s keep the momentum going, because progress happens every day!
-
-
In case you missed it, our Chief Financial & Business Officer Molly Henderson recently sat down with other industry leaders for the FT Live panel “Making a Business Case to Fund an Upcoming Launch.” The conversation covered key strategies for securing pre-launch funding, common pitfalls companies face when presenting their business case, and how biotech leaders can make smart investment decisions to maximize launch success. The discussion offered valuable takeaways for organizations preparing for an upcoming launch or refining their funding strategies. Watch the full panel discussion here: https://bit.ly/4l0rHX9
-